Meeting
2018 ASCO Annual Meeting
PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).
Authors
Jaafar Bennouna
Centre Hospitalier Universitaire Nantes, Digestive Oncology, Nantes, France
Jaafar Bennouna , Thierry Andre , Laurent Miglianico , Loic Campion , Laurent Mineur , You Heng Lam , Sandrine Hiret , Pascal Artru , Olivier Bouche , Florence Borde , Albert Aleba , Laetitia-Shanna Rajpar , Christine Rebischung , Yann Touchefeu , Petr Kavan , Sharlene Gill , Tim Asmis , Claire Jouffroy-Zeller , Jean-François Emile , Julien Taieb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02967289
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3622)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3622
Abstract #
TPS3622
Poster Bd #
111b
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan Clinical Oncology Group study (JCOG0205).
First Author: Yasuhiro Shimada
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).
First Author: Thomas J. George
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers